Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
Settings
PCYC [NASD]
Pharmacyclics Inc.
Index- P/E59.38 EPS (ttm)1.76 Insider Own0.40% Shs Outstand75.02M Perf Week14.21%
Market Cap7.84B Forward P/E701.34 EPS next Y0.15 Insider Trans-10.45% Shs Float60.78M Perf Month18.15%
Income137.20M PEG371.09 EPS next Q-0.26 Inst Own71.10% Short Float9.25% Perf Quarter10.61%
Sales376.70M P/S20.81 EPS this Y-45.30% Inst Trans-0.20% Short Ratio4.33 Perf Half Y-25.72%
Book/sh8.89 P/B11.75 EPS next Y-10.24% ROA19.60% Target Price148.63 Perf Year2.96%
Cash/sh9.20 P/C11.36 EPS next 5Y0.16% ROE24.00% 52W Range82.51 - 154.89 Perf YTD-1.21%
Dividend- P/FCF60.82 EPS past 5Y24.50% ROI10.70% 52W High-32.56% Beta0.82
Dividend %- Quick Ratio7.80 Sales past 5Y- Gross Margin97.50% 52W Low26.60% ATR3.88
Employees499 Current Ratio8.10 Sales Q/Q4094.60% Oper. Margin51.50% RSI (14)69.67 Volatility4.80% 3.90%
OptionableYes Debt/Eq0.00 EPS Q/Q131.50% Profit Margin36.40% Rel Volume1.13 Prev Close104.50
ShortableYes LT Debt/Eq0.00 EarningsJul 28 Payout0.00% Avg Volume1.30M Price104.46
Recom2.20 SMA2010.20% SMA5011.26% SMA200-7.35% Volume295,615 Change-0.04%
27-May-14Downgrade RBC Capital Mkts Outperform → Sector Perform $110 → $95
05-May-14Reiterated RBC Capital Mkts Outperform $150 → $110
21-Feb-14Reiterated Deutsche Bank Buy $170 → $180
18-Dec-13Initiated WallachBeth Hold $108
26-Sep-13Initiated Deutsche Bank Buy $170
12-Dec-12Reiterated Wedbush Outperform $93 → $110
24-Aug-12Initiated Stifel Nicolaus Hold
02-Aug-12Downgrade Needham Buy → Hold
17-May-12Reiterated Rodman & Renshaw Mkt Outperform $22 → $40
17-May-12Reiterated Needham Buy $23 → $32
21-Feb-12Upgrade RBC Capital Mkts Sector Perform → Outperform $15 → $34
09-Dec-11Downgrade RBC Capital Mkts Outperform → Sector Perform $15 → $15
09-Dec-11Downgrade Global Hunter Securities Buy → Neutral $15 → $15
07-Dec-11Initiated Rodman & Renshaw Mkt Outperform $20
11-Nov-11Resumed Needham Buy $14
20-Jun-11Reiterated RBC Capital Mkts Outperform $10 → $15
07-Jun-10Reiterated Wedbush Outperform $8 → $16
14-Apr-10Reiterated Roth Capital Buy $7 → $11
12-Mar-10Initiated Roth Capital Buy $7
12-Feb-10Downgrade BWS Financial Buy → Hold
25-Jul-14 08:52AM  European Medicines Agency (EMA) Issues Positive Opinion, Recommends Full Approval of IMBRUVICA® (ibrutinib) for Treatment of Two Blood Cancers PR Newswire
08:32AM  Why Gilead Stock's Newest Drug Approval Isn't a Gamechanger at Motley Fool
24-Jul-14 07:38AM  Can the Rally in Pharmacyclics (PCYC) Shares Continue? Zacks
23-Jul-14 06:11PM  Is Gilead About to Crush Pharmacyclics Stock? at Motley Fool +7.57%
09-Jul-14 07:51PM  Is Pharmacyclics the Next Celgene? at Motley Fool
08-Jul-14 08:01AM  Halozyme Attracting Attention With Upcoming Adcom And Potential Blockbuster Pancreatic Cancer Treatment at Seeking Alpha
06:00AM  3 Stocks Spiking on Unusual Volume at TheStreet
24-Jun-14 05:05PM  [video] Upside ahead for Vertex: Pro at CNBC
05:05PM  [video] Upside ahead for Vertex: Pro
21-Jun-14 09:02AM  3 Stocks Crushed by the Market This Week at Motley Fool
09:02AM  3 Stocks Crushed by the Market This Week
19-Jun-14 05:39PM  Fire Up The Immuno-Oncology Powerhouses: John McCamant at Seeking Alpha
10-Jun-14 05:45PM  Pharmacyclics' Imbruvica Under FDA Priority Review Zacks
05:45PM  Pharmacyclics' Imbruvica Under FDA Priority Review
09-Jun-14 06:41PM  Pharmacyclics Investor's Business Daily
06:41PM  Pharmacyclics
08:18AM  Pharmacyclics reports sNDA for Imbruvica accepted, priority review granted at theflyonthewall.com
08:18AM  Pharmacyclics reports sNDA for Imbruvica accepted, priority review granted
08:00AM  Supplemental New Drug Application for IMBRUVICA® Accepted by the U.S. FDA and Priority Review Granted PR Newswire
08:00AM  Supplemental New Drug Application for IMBRUVICA® Accepted by the U.S. FDA and Priority Review Granted
06-Jun-14 01:03PM  PCYC, ALXN And PFE, 3 Drugs Stocks Pushing The Industry Lower at TheStreet
01:03PM  PCYC, ALXN And PFE, 3 Drugs Stocks Pushing The Industry Lower
05-Jun-14 01:26PM  PHARMACYCLICS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits EDGAR Online
01:26PM  PHARMACYCLICS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
11:28AM  ASCO: Cancer Drug Showdown at Motley Fool
07:36AM  The Zacks Analyst Blog Highlights: Pharmacyclics, AbbVie, Gilead, Amgen and Celgene. Zacks
04-Jun-14 11:14AM  Biotech Stock Roundup: Gilead, Pharmacyclics Impress at ASCO Zacks
09:39AM  1 Biotech Steamrolling the Competition at Motley Fool
09:39AM  1 Biotech Steamrolling the Competition
07:11AM  The Zacks Analyst Blog Highlights: Bristol-Myers Squibb, Merck, Roche, Pharmacyclics and AbbVie Zacks
03-Jun-14 08:02AM  UPDATE: Morgan Stanley Reiterates On Pharmacyclics Following Investor Event Benzinga
08:02AM  UPDATE: Morgan Stanley Reiterates On Pharmacyclics Following Investor Event
07:20AM  Gorman Rupp, American Vanguard, Pharmacyclics, GlaxoSmithKline and Johnson & Johnson highlighted as Zacks Bull and Bear of the Day Zacks
07:20AM  Gorman Rupp, American Vanguard, Pharmacyclics, GlaxoSmithKline and Johnson & Johnson highlighted as Zacks Bull and Bear of the Day
02-Jun-14 01:26PM  IMBRUVICA® (ibrutinib) Significantly Improves Progression Free Survival, Overall Survival and Overall Response as compared to Ofatumumab in Patients with Previously Treated CLL/SLL in its First Phase III study PR Newswire
01:25PM  Pharmacyclicss Imbruvica Continues to Set the Bar High for Cancer Drugs at Wall St. Cheat Sheet
12:20PM  Midday movers: Allergan, Valeant, US Steel & more at CNBC
11:10AM  Encouraging Data on Pharmacyclics/J&J Drug Zacks
10:42AM  US STOCKS-Wall St dips after manufacturing data, Google falls Reuters
09:44AM  Why these 3 biotech stocks are making big moves at CNBC
08:11AM  Why these 3 biotech stocks are making big moves at CNBC
08:11AM  Why Clovis, Ariad, Pharmacyclics are on the move at CNBC
31-May-14 03:29PM  Pharmacyclics Leukemia Drug Beats Glaxos in Clinical Trial at Bloomberg
08:05AM  IMBRUVICA® (ibrutinib) Significantly Improves Progression Free Survival, Overall Survival and Overall Response as compared to Ofatumumab in Patients with Previously Treated CLL/SLL in its First Phase III study PR Newswire
08:05AM  IMBRUVICA® (ibrutinib) Shows Durable, Long-Term Responses for Patients with CLL PR Newswire
08:05AM  IMBRUVICA® (ibrutinib) Combination with anti CD20 Antibody Shows Compelling Results in Heavily Pretreated Patients with CLL and Related Diseases PR Newswire
07:35AM  Pharmacyclics' Imbruvica Extends Survival in Elderly Leukemia Patients at TheStreet
29-May-14 01:02PM  3 Drugs Stocks Dragging The Industry Down at TheStreet
08:20AM  3 More Surges In Biotech Short Interest (AMGN, MDVN, PCYC) Benzinga
28-May-14 09:36AM  3 Stocks Crushed by the Market Last Week at Motley Fool
09:17AM  Doctors enthusiastic about Pharmacyclics Imbruvica, says JMP Securities at theflyonthewall.com
27-May-14 09:55AM  UPDATE: Morgan Stanley Reiterates On Pharmacyclics Following IMS Launch Analysis Benzinga
09:01AM  Pharmacyclics downgraded to Sector Perform from Outperform at RBC Capital at theflyonthewall.com
09:01AM  Will This Downgrade Hurt Pharmacyclis (PCYC) Stock Today? at TheStreet
06:20AM  Pharmacyclics downgraded by RBC Capital Mkts Briefing.com
23-May-14 07:02PM  Why Pharmacyclics, Inc., Matador Resources Co, and Twitter Inc Are Today's 3 Worst Stocks at Motley Fool -7.35%
03:49PM  Mid-Afternoon Market Update: Nimble Storage Rallies As Pharmacyclics Shows Weakness Benzinga
01:40PM  Nasdaq stocks posting largest percentage decreases AP
01:16PM  Pharmacyclics down after announcing resignation of Paula Boultbee at theflyonthewall.com
10:16AM  PHARMACYCLICS INC Files SEC form 8-K, Change in Directors or Principal Officers EDGAR Online
21-May-14 08:00AM  The Bull Thesis for Pharmacyclics Into ASCO '14 at TheStreet
20-May-14 08:00AM  Pharmacyclics appoints Gregory R. Wade to lead Business Development PR Newswire
19-May-14 09:31AM  1 Biotech Refusing to Stick Its Neck Out at Motley Fool
16-May-14 06:01AM  PHARMACYCLICS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits EDGAR Online
15-May-14 09:26AM  Nomura is a buyer of Incyte and Pharmacyclics into ASCO meetings at theflyonthewall.com
07:14AM  AbbVie, Roche drug a real threat to Pharmacyclics, says Bernstein at theflyonthewall.com
05:40AM  ASCO abstracts 'surprisingly bland,' says Piper Jaffray at theflyonthewall.com
14-May-14 06:26PM  Pharmacyclics presents new data for IMBRUVICA at theflyonthewall.com
06:22PM  Pharmacyclics Highlights Important New Data for IMBRUVICA® (ibrutinib) in B-Cell Malignancies PR Newswire
04:16PM  PHARMACYCLICS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in Directors or Principal Of EDGAR Online
01:04PM  PHARMACYCLICS INC Financials EDGAR Online Financials
12:02AM  The ASCO Abstracts Are Coming at Motley Fool
13-May-14 07:49AM  Forget Rent: The Cost of These 5 New Drugs Is Too Damn High at Wall St. Cheat Sheet
11-May-14 04:35PM  Surges In Biotech Short Interest (INCY, PCYC, RGEN) Benzinga
08-May-14 06:22AM  The Zacks Analyst Blog Highlights: Endocyte, Acorda, Pharmacyclics, OncoGenex and Merrimack Zacks
06:05AM  PHARMACYCLICS INC Files SEC form 10-Q, Quarterly Report EDGAR Online
07-May-14 02:31PM  1 Company Johnson & Johnson Should Buy at Motley Fool
06:01AM  PHARMACYCLICS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits EDGAR Online
05-May-14 10:30AM  Earnings Beat at Pharmacyclics, Guidance Pulls Down Stock Zacks +8.00%
02-May-14 03:47PM  Pharmacyclics' CEO Discusses Q1 2014 Results - Earnings Call Transcript at Seeking Alpha -7.44%
02:24PM  Why Pharmacyclics, Inc. Shares Stumbled Out of the Gate at Motley Fool
01:06PM  Today's 3 Biotech Blow-Ups at Motley Fool
12:29PM  Midday movers: Chevron, Nutrisystem, Skechers & More at CNBC
08:20AM  PHARMACYCLICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibit EDGAR Online
08:00AM  Pharmacyclics Reports First Quarter 2014 Results PR Newswire
07:25AM  Biotechnology Capital Inflows Reach Historic Highs: A Wall Street Transcript Interview with Brian Skorney, a Senior Analyst with Robert W. Baird & Co. Covering Biotechnology Wall Street Transcript
07:07AM  Q1 2014 Pharmacyclics Inc. Earnings Release - Before Market Open CCBN
28-Apr-14 09:50AM  Drugs That Disappointed Investors In 2013: Infinity's IPI-145 at Seeking Alpha
25-Apr-14 12:30PM  AbbVie Beats Q1 Estimates, Downplays HCV 'Price War' at Investor's Business Daily -6.12%
11:40AM  Thomas B. King, the President, CEO and Director of Alexza Pharmaceutical, Inc. (ALXA), Interviews with The Wall Street Transcript Wall Street Transcript
10:45AM  Pharmacyclics Announces Date of Conference call to discuss Financial Results for First Quarter of 2014 PR Newswire
22-Apr-14 09:32AM  Why Johnson & Johnson Is Outperforming the Dow at Motley Fool
21-Apr-14 04:47PM  PHARMACYCLICS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits EDGAR Online
11:45AM  Pharmacyclics Announces Presentation of Phase III and Long Term Follow Up Data on IMBRUVICA in Chronic Lymphocytic Leukemia (CLL) at ASCO PR Newswire
17-Apr-14 08:48AM  The Zacks Analyst Blog Highlights: GIlead, AbbVie, MannKind, Alkermes and Pharmacyclics Zacks
04:41AM  Cramer's Lightning Round - Gigamon Is In The Penalty Box (4/16/14) at Seeking Alpha
16-Apr-14 06:47PM  Lightning Round: Southwest Airlines, Blackstone & More at CNBC
06:30AM  A Lucky Drug Made Pharmacyclics' Robert Duggan A Billionaire. Will Long-Term Success Follow? at Forbes
15-Apr-14 12:23PM  The Recent Performance of 'Baker Brother Biotech Stocks' is Awful at TheStreet
10:06AM  J&J beats forecasts, helped by new medicines at CNBC
Pharmacyclics, Inc., a biopharmaceutical company, designs, develops, and commercializes small-molecule drugs for the treatment of cancer and immune mediated diseases in the United States and internationally. The company offers IMBRUVICATM as a single agent for the treatment of patients with chronic lymphocytic leukemia who have received at least one prior therapy. Its products candidate in clinical development includes IMBRUVICA BTK inhibitor, which is under multiple Phase I, II, III clinical trials for the treatment of naive and relapsed/refractory chronic lymphocytic leukemia, naive and relapsed/refractory diffuse large B-cell lymphoma, naive follicular lymphoma, relapsed/refractory mantle cell lymphoma, relapsed/refractory follicular lymphoma, relapsed/refractory multiple myeloma, Waldenstrom's macroglobulinemia, and relapsed/refractory marginal zone lymphoma. The company is also developing a BTK inhibitor lead optimization program, which is in Phase I clinical trials targeting anti-inflammatory and autoimmune indications; PCI-27483, an inhibitor of Factor VIIa that is in multiple Phase I, II clinical trials for the treatment of cancer; and PCI-24781, a HDAC inhibitor abexinostat, which is in multiple Phase I, II clinical trials for the treatment of relapsed/refractory lymphomas and solid tumors. The company's clinical development and product candidates are small-molecule enzyme inhibitors designed to target key biochemical pathways involved in human diseases with critical unmet needs. It has a collaboration and license agreement with Janssen Biotech, Inc. to develop and commercialize ibrutinib and related compounds; collaboration and license agreement with Les Laboratoires Servier to develop and commercialize abexinostat; and license agreement with Novo Nordisk A/S to research and develop PCI-27483. Pharmacyclics, Inc. was founded in 1991 and is headquartered in Sunnyvale, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Sjovall Boultbee Paula SEVP, Sales and MarketingMay 08Option Exercise25.947,710199,9979,653May 08 06:41 PM
Sjovall Boultbee Paula SEVP, Sales and MarketingApr 29Option Exercise57.162,332133,2972,728May 01 06:14 PM
Fardis MariaChief of Oncology Ops & AllianMar 05Option Exercise6.843,00020,5205,988Mar 07 06:06 PM
Hemmi GregorySr. VP Chemical OperationsMar 05Option Exercise0.8615,00012,90053,004Mar 06 06:06 PM
Sjovall Boultbee Paula SEVP, Sales and MarketingMar 05Option Exercise25.946,253162,2037,992Mar 06 04:33 PM
McGreivy JesseChief Medical OfficerMar 05Option Exercise25.336,563166,2416,563Mar 06 04:35 PM
McGreivy JesseChief Medical OfficerMar 05Sale139.666,563916,5990Mar 06 04:35 PM
Sjovall Boultbee Paula SEVP, Sales and MarketingMar 05Sale140.756,253880,1151,739Mar 06 04:33 PM
Hemmi GregorySr. VP Chemical OperationsMar 05Sale140.0015,0002,100,03338,004Mar 06 06:06 PM
Fardis MariaChief of Oncology Ops & AllianMar 05Sale140.503,000421,5042,988Mar 07 06:06 PM
Chang Betty YVP, Research/BiologyMar 04Option Exercise10.2417,500179,23821,254Mar 05 08:15 PM
HALVORSON ERIC HDirectorMar 04Option Exercise17.663,47261,3324,472Mar 06 02:46 PM
Sjovall Boultbee Paula SEVP, Sales and MarketingMar 04Option Exercise25.9413,747356,59715,486Mar 06 04:33 PM
Sjovall Boultbee Paula SEVP, Sales and MarketingMar 04Sale137.0713,7471,884,3301,739Mar 06 04:33 PM
HALVORSON ERIC HDirectorMar 04Sale138.333,472480,2821,000Mar 06 02:46 PM
Chang Betty YVP, Research/BiologyMar 04Sale137.9717,5002,414,4843,754Mar 05 08:15 PM
van den Broek RichardDirectorFeb 27Sale144.9225,0003,622,99029,610Feb 28 05:26 PM
van den Broek RichardDirectorFeb 26Sale147.1325,6803,778,17054,610Feb 28 05:26 PM
van den Broek RichardDirectorFeb 25Sale147.7028,1554,158,49680,290Feb 28 05:26 PM
Hemmi GregoryVP Chemical OperationsDec 30Option Exercise0.7513,0009,75038,004Jan 02 01:15 PM
Tan HeowChief Quality&Tech OperationsDec 24Option Exercise27.051,50040,5751,669Dec 26 06:10 PM
Smith David DuaneDirectorDec 20Option Exercise1.921,0001,9203,000Dec 20 05:22 PM
Tan HeowChief Quality&Tech OperationsDec 19Option Exercise27.055,000135,2505,169Dec 20 02:44 PM
Tan HeowChief Quality&Tech OperationsDec 19Sale100.875,000504,352169Dec 20 02:44 PM
Hemmi GregoryVP Chemical OperationsDec 18Option Exercise0.8610,0008,60035,004Dec 18 07:30 PM
Hemmi GregoryVP Chemical OperationsDec 18Sale99.0410,000990,38025,004Dec 18 07:30 PM
Hemmi GregoryVP Chemical OperationsDec 17Option Exercise0.8610,0008,60035,004Dec 18 07:30 PM
Hemmi GregoryVP Chemical OperationsDec 17Sale102.0010,0001,020,00025,004Dec 18 07:30 PM
Erdtmann Rainer MSr. VP, IR and AdminDec 16Option Exercise0.9122,83520,78034,332Dec 16 07:13 PM
Smith David DuaneDirectorDec 16Option Exercise1.926,50012,4808,500Dec 17 04:16 PM
Zanganeh MakyChief Operating OfficerDec 16Sale107.5520,0002,151,000210,107Dec 18 07:24 PM
Erdtmann Rainer MSr. VP, IR and AdminDec 16Sale107.7222,8352,459,68111,497Dec 16 07:13 PM
Erdtmann Rainer MSr. VP, IR and AdminDec 13Option Exercise0.9131,16528,36042,662Dec 16 07:13 PM
Erdtmann Rainer MSr. VP, IR and AdminDec 13Sale107.8231,1653,360,11411,497Dec 16 07:13 PM